186 related articles for article (PubMed ID: 8855976)
1. Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.
Schuyer M; van Staveren IL; Klijn JG; vd Burg ME; Stoter G; Henzen-Logmans SC; Foekens JA; Berns EM
Br J Cancer; 1996 Oct; 74(7):1069-73. PubMed ID: 8855976
[TBL] [Abstract][Full Text] [Related]
2. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
3. Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours.
Marchini S; Codegoni AM; Bonazzi C; Chiari S; Broggini M
Br J Cancer; 1997; 76(2):146-9. PubMed ID: 9231912
[TBL] [Abstract][Full Text] [Related]
4. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.
Yaginuma Y; Hayashi H; Kawai K; Kurakane T; Saitoh Y; Kitamura S; Sengoku K; Ishikawa M
Exp Cell Res; 1997 Jun; 233(2):233-9. PubMed ID: 9194486
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
8. LOH and mutation analysis of CDKN2 in primary human ovarian cancers.
Campbell IG; Foulkes WD; Beynon G; Davis M; Englefield P
Int J Cancer; 1995 Oct; 63(2):222-5. PubMed ID: 7591208
[TBL] [Abstract][Full Text] [Related]
9. The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
Raffel C; Ueki K; Harsh GR; Louis DN
Neurosurgery; 1995 May; 36(5):971-4; discussion 974-5. PubMed ID: 7791990
[TBL] [Abstract][Full Text] [Related]
10. Alterations of CDKN2 (p16) in non-small cell lung cancer.
de Vos S; Miller CW; Takeuchi S; Gombart AF; Cho SK; Koeffler HP
Genes Chromosomes Cancer; 1995 Nov; 14(3):164-70. PubMed ID: 8589032
[TBL] [Abstract][Full Text] [Related]
11. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
12. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas.
Bartsch D; Shevlin DW; Tung WS; Kisker O; Wells SA; Goodfellow PJ
Genes Chromosomes Cancer; 1995 Nov; 14(3):189-95. PubMed ID: 8589035
[TBL] [Abstract][Full Text] [Related]
13. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
14. Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage.
Nakao M; Yokota S; Kaneko H; Seriu T; Koizumi S; Takaue Y; Fujimoto T; Misawa S
Leukemia; 1996 Feb; 10(2):249-54. PubMed ID: 8637233
[TBL] [Abstract][Full Text] [Related]
15. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK
Oncogene; 1995 Mar; 10(6):1061-7. PubMed ID: 7700630
[TBL] [Abstract][Full Text] [Related]
16. The CDKN2 gene alterations in various types of adult T-cell leukaemia.
Uchida T; Kinoshita T; Watanabe T; Nagai H; Murate T; Saito H; Hotta T
Br J Haematol; 1996 Sep; 94(4):665-70. PubMed ID: 8826890
[TBL] [Abstract][Full Text] [Related]
17. Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens.
Calvano JE; Rush EB; Tan LK; Rosen PP; Borgen PI; Van Zee KJ
Ann Surg Oncol; 1997; 4(5):416-20. PubMed ID: 9259969
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.
Xu L; Sgroi D; Sterner CJ; Beauchamp RL; Pinney DM; Keel S; Ueki K; Rutter JL; Buckler AJ; Louis DN
Cancer Res; 1994 Oct; 54(20):5262-4. PubMed ID: 7923151
[TBL] [Abstract][Full Text] [Related]
19. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK
Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas.
Uchida T; Watanabe T; Kinoshita T; Murate T; Saito H; Hotta T
Blood; 1995 Oct; 86(7):2724-31. PubMed ID: 7670111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
